Context Therapeutics (NASDAQ:CNTX) Stock Rating Lowered by Lifesci Capital

Context Therapeutics (NASDAQ:CNTX) was downgraded by stock analysts at Lifesci Capital from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

A number of other research analysts have also recently issued reports on CNTX. Maxim Group cut their price target on Context Therapeutics from $8.00 to $4.00 and set a “buy” rating for the company in a report on Tuesday, June 16th. Weiss Ratings lowered shares of Context Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday. Citigroup restated an “outperform” rating on shares of Context Therapeutics in a research report on Thursday. Finally, Wall Street Zen downgraded shares of Context Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, July 20th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $6.17.

Context Therapeutics Stock Performance

Shares of CNTX opened at $0.48 on Thursday. The stock has a fifty day moving average price of $0.86 and a two-hundred day moving average price of $1.91. Context Therapeutics has a 52-week low of $0.48 and a 52-week high of $3.62. The company has a market cap of $44.47 million, a price-to-earnings ratio of -1.01 and a beta of 1.74.

Context Therapeutics (NASDAQ:CNTX) last announced its earnings results on Wednesday, August 5th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.06). As a group, research analysts predict that Context Therapeutics will post -0.39 EPS for the current fiscal year.

Institutional Trading of Context Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CNTX. Sanctuary Advisors LLC bought a new stake in Context Therapeutics during the 1st quarter worth about $51,000. Virtu Financial LLC acquired a new stake in shares of Context Therapeutics during the 4th quarter worth approximately $43,000. Quadrature Capital Ltd bought a new stake in shares of Context Therapeutics during the 4th quarter valued at $68,000. OMERS ADMINISTRATION Corp bought a new stake in Context Therapeutics in the first quarter valued at about $211,000. Finally, Deutsche Bank AG bought a new stake in shares of Context Therapeutics in the 2nd quarter valued at about $50,000. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.